Skip to main content
SpringerLink
Log in

Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase. However, several new therapies have been developed. Recombinant urate oxidase has been useful in the treatment of tumor lysis hyperuricemia, and pegylated urate oxidase shows promise in patients with hyperuricemia and gout. Febuxostat and Y-700 are new oral xanthine oxidase inhibitors that are in human clinical trials. Tailoring of antilipid therapy in selected hyperuricemic and hyperlipidemic patients with fenofibrate may be of benefit in lowering blood cholesterol and uric acid levels. Similarly, treatment of selected hyperuricemic patients who also are hypertensive with losartan or amlodipine may be beneficial in lowering blood pressure and hyperuricemia. Despite these advances, new treatments for hyperuricemia are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Arrondee E, Michet CJ, Crowson CS, et al.: Epidemiology of gout: is the incidence rising? J Rheumatol 2002, 29:2403–2406.

    Google Scholar 

  2. Zeng Q, Wang Q, Ren C, et al.: Primary gout in Shantou: a clinical and epidemiological study. Chin Med J 2003, 116:66–69.

    PubMed  Google Scholar 

  3. Chen SY, Chen CL, Shen ML, Kamatani N: Trends in the manifestations of gout in Taiwan. Rheumatology 2003, 42:1529–1533.

    Article  PubMed  Google Scholar 

  4. Liu CS, Li TC, Lin CC: The epidemiology of hyperuricemia in children of Taiwan aborigines. J Rheumatol 2003, 30:841–845.

    PubMed  CAS  Google Scholar 

  5. Bonet LA: Predictors of mortality following heart transplantation: Spanish Registry of Heart Transplantation 1984–2001. Transplant Proc 2003, 35:1946–1950.

    Article  PubMed  CAS  Google Scholar 

  6. Moreno JM, Cuervas-Mons V, Rubio E, et al.: Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc 2003, 35:1907–1908.

    Article  PubMed  CAS  Google Scholar 

  7. Johnson RJ, Kang DH, Feig D, et al.: Is there a pathogenetic role for uric acid in hypertension and renal disease? Hypertension 2003, 41:1183–1190. Review article describing the association of hyperuricemia with hypertension, vascular disease, renal disease, and cardiovascular events.

    Article  PubMed  CAS  Google Scholar 

  8. Cardona F, Tinahones FJ, Collantes E, et al.: The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. Rheumatology 2003, 42:468–472.

    PubMed  CAS  Google Scholar 

  9. Terkeltaub RA: Clinical practice: gout. N Engl J Med 2003, 349:1647–1655. Excellent review article on gout using a patient presentation as a springboard for discussion. Includes easy-to-read figures and tables that summarize treatment regimens and considerations in therapy.

    Article  PubMed  CAS  Google Scholar 

  10. Rott KT, Agudelo CA: Gout. JAMA 2003, 289:2857–2860. Excellent review article on gout emphasizing comorbidities and characteristics of classic versus atypical gout.

    Article  PubMed  Google Scholar 

  11. Pay S, Terkeltaub RA: The case for uricase in gout. Curr Rheumatol Rep 2003, 5:213–214. Short article focusing on the potential usefulness of uricase formulated with polyethylene glycol.

    Article  PubMed  Google Scholar 

  12. Oda M, Satta Y, Takenaka O, Takahata N: Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002, 19:640–653.

    PubMed  CAS  Google Scholar 

  13. Bayol A, Capdevvielle J, Malazzi P, et al.: Modification of a reactive cysteine explains differences between rasburicase and uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem 2002, 36:21–31.

    Article  PubMed  CAS  Google Scholar 

  14. Pui C-H, Mahmoud HM, Wiley JM, et al.: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001, 19:697–704.

    PubMed  CAS  Google Scholar 

  15. Pui C-H, Jeha S, Irwin D, Camitta B: Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001, 15:1505–1509.

    Article  PubMed  CAS  Google Scholar 

  16. Pui C-H: Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001, 38(suppl):13–21.

    Article  PubMed  CAS  Google Scholar 

  17. Goldman ST, Holcenberg JS, Finklestein JZ, et al.: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97:2998–3003.

    Article  PubMed  CAS  Google Scholar 

  18. Pui C-H: Rasburicase: a viewpoint. Paediatr Drugs 2001, 3:438.

    Article  Google Scholar 

  19. Goldman S: Rasburicase: a viewpoint. Paediatr Drugs 2001, 3:439.

    Article  Google Scholar 

  20. Lim E, Bennett P, Beilby J: Sample preparation in patients receiving uric acid oxidase (rasburicase) therapy. Clin Chem 2003, 49:1417–1419.

    Article  PubMed  CAS  Google Scholar 

  21. van den Berg H, Reintsema AM: Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol 2004, 5:175–176.

    Article  Google Scholar 

  22. Pui C-H: Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 2002, 3:433–442.

    Article  PubMed  CAS  Google Scholar 

  23. Holdsworth MT, Nguyen P: Role of iv allopurinol and rasburicase in tumor lysis syndrome. Am J Health Syst Pharm 2003, 60:2213–2222.

    PubMed  CAS  Google Scholar 

  24. Yim BT, Sims-McCallum RP, Chong PH: Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003, 37:1047–1054.

    Article  PubMed  CAS  Google Scholar 

  25. Annemans L, Moeremans K, Lamotte M, et al.: Pan-European multicenter economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricemia and tumor lysis syndrome in hematological cancer patients. Support Care Cancer 2003, 11:249–257.

    PubMed  CAS  Google Scholar 

  26. Cairo MS: Prevention and treatment of hyperuricemia in hematological malignancies. Clin Lymphoma 2002, 3(suppl):S26-S31.

    Article  PubMed  Google Scholar 

  27. Hummel M, Buchheidt D, Reiter S, et al.: Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003, 17:2452–2544.

    Article  Google Scholar 

  28. Lee AC, Li CH, So KT, Chan R: Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003, 37:1614–1617.

    Article  PubMed  Google Scholar 

  29. Navolanic PM, Pui C-H, Larson RA, et al.: Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 2003, 17:499–514. A meeting report on the role of rasburicase in tumor lysis hyperuricemia.

    Article  PubMed  CAS  Google Scholar 

  30. Goldman S: Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther 2003, 3:89–93.

    Article  Google Scholar 

  31. Ribeiro RC, Pui C-H: Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma 2003, 3:225–232.

    PubMed  CAS  Google Scholar 

  32. Bosly A, Sonet A, Pinkerton CR, et al.: Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003, 98:1048–1054.

    Article  PubMed  CAS  Google Scholar 

  33. Coiffier B, Mounier N, Bologna S, et al.: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial) on rasburicase activity in adult lymphoma study. J Clin Oncol 2003, 21:4402–4406.

    Article  PubMed  CAS  Google Scholar 

  34. Harris JM, Chess RB: Effect of pegylation on pharmaceuticals. Nature Rev Drug Disc 2003, 2:214–221. Excellent short review on the principles of pegylation and application to biologics.

    Article  CAS  Google Scholar 

  35. Kelly SJ, Delnomdedieu M, Oliverio MI, et al.: Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 2001, 12:1001–1009.

    PubMed  CAS  Google Scholar 

  36. Vivarès D, Bonneté F: X-ray scattering studies of Aspergillus flavus urate oxidase: towards a better understanding of PEG effects on the crystallization of large proteins. Acta Cryst 2002, D58:472–479.

    Google Scholar 

  37. Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA: Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002, 29:1942–1949. Description of the rationale for choosing C. utilis uricase and polyethylene glycol of 20,000 mw to optimize formulation of the enzyme, and results from preclinical testing.

    PubMed  CAS  Google Scholar 

  38. Bomalaski JS, Goddard DH, Grezlak D, et al.: Phase I study of uricase formulated with polyethylene glycol (uricase- PEG 20). Arthritis Rheum 2002, 46(suppl):S141.

    Google Scholar 

  39. Silveria LH, Vargas A, Medina MN: Use of low-dose prednisone in the treatment of the acute gouty attack (AGA). Arthritis Rheum 2003, 48(suppl):S535.

    Google Scholar 

  40. Borges F, Fernandes E, Roleira F: Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem 2002, 9:195–217.

    PubMed  CAS  Google Scholar 

  41. Owen PL, Johns T: Xanthine oxidase inhibitory activity of northeastern North American plant remedies used for gout. J Ethnopharmacol 1999, 64:149–160.

    Article  PubMed  CAS  Google Scholar 

  42. Kong LD, Cai Y, Huang WW, et al.: Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout. J Ethnopharmacol 2000, 73:199–207.

    Article  PubMed  CAS  Google Scholar 

  43. Fernandes E, Carvalho F, Silva AM, et al.: 2-styrylchromones as novel inhibitors of xanthine oxidase: a structure-activity study. J Enzyme Inhib Med Chem 2002, 17:45–48.

    Article  PubMed  CAS  Google Scholar 

  44. Isibuchi S, Morimoto H, Oe T, et al.: Synthesis and structureactivity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. Bioorg Med Chem Lett 2001, 11:879–882.

    Article  Google Scholar 

  45. Osajima T, Kamezawa M, Fukunari A, et al.: Pharmacokinetics and pharmacodynamics of Y-700, a potent and non-renal excretion type of xanthine oxidase inhibitor, in healthy male volunteers. Arthritis Rheum 2003, 48(suppl):S530.

    Google Scholar 

  46. Noma S, Verho M, Iwane, et al.: Safety, tolerability, pharmacokinetics, and lowering uric acid effect of repeated daily dosing with Y-700, a novel xanthine oxidase inhibitor, in health male volunteers. Arthritis Rheum 2003, 48(suppl):S530.

    Google Scholar 

  47. Okamoto K, Eger BT, Nishino T, et al.: An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of action. J Biol Chem 2003, 278:1848–1855.

    Article  PubMed  CAS  Google Scholar 

  48. Zhao L, Takano Y, Horiuchi H: Effect of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase (NPSIXO) on enzymes in purine and pyrimidine metabolism pathway. Arthritis Rheum 2003, 48(suppl):S531.

    Google Scholar 

  49. Swan S, Khosravan R, Mayer MD, et al.: Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase. Arthritis Rheum 2003, 48(suppl):S529.

    Google Scholar 

  50. Kamatani N, Fujimori S, Hada T, et al.: Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/xanthine dehydrogenase inhibitor, for gout and hyperuricemia. Arthritis Rheum 2003, 48(suppl):S530.

    Google Scholar 

  51. Takahashi S, Moriwaki Y, Yamamoto T, et al.: Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003, 62:572–575.

    Article  PubMed  CAS  Google Scholar 

  52. Hepburn AL, Kaye SA, Feher MD: Fenofibrate: a new treatment for hyperuricemia and gout? Ann Rheum Dis 2001, 60:984–986.

    Article  PubMed  CAS  Google Scholar 

  53. Elisaf M, Tsimichodimos V, Bairaktari E, et al.: Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 1999, 34:60–63.

    Article  PubMed  CAS  Google Scholar 

  54. Feher MD, Hepburn AL, Hogarth MB, et al.: Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology 2003, 42:321–325.

    Article  PubMed  CAS  Google Scholar 

  55. Hepburn AL, Kaye SA, Feher MD: Long-term remission from gout associated with fenofibrate therapy. Clin Rheumatol 2003, 22:73–76.

    Article  PubMed  CAS  Google Scholar 

  56. Millionis HJ, Elisaf MS: Management of hypertension and dyslipidaemia in patients presenting with hyperuricemia: case histories. Curr Med Res Opin 2000, 16:164–170.

    Article  Google Scholar 

  57. Achimastos A, Liberopoulos E, Nikas S, et al.: The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. Curr Med Res Opin 2002, 18:59–63.

    Article  PubMed  CAS  Google Scholar 

  58. Bardin T: Fenofibrate and losartan. Ann Rheum Dis 2003, 62:497–498.

    Article  PubMed  CAS  Google Scholar 

  59. Ito O, Hasegawa Y, Sato K, et al.: A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide. Hypertension Res 2003, 26:509–513.

    Article  Google Scholar 

  60. Chanard J, Toupance O, Lavaud S, et al.: Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003, 18:2147–2153.

    Article  PubMed  CAS  Google Scholar 

  61. Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, et al.: Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant 2003, 18:603–606.

    Article  PubMed  CAS  Google Scholar 

  62. Jacob RA, Spinozzi GM, Simon VA, et al.: Consumption of cherries lowers plasma urate in healthy women. J Nutr 2003, 133:1826–1829.

    PubMed  CAS  Google Scholar 

  63. Facchini FS: Near-iron deficiency-induced remission in gouty arthritis. Rheumatology 2003, 42:1550–1555.

    Article  PubMed  CAS  Google Scholar 

  64. Rull M, Clayburne G, Sieck M, Schumacher HR: Intra-articular corticosteroid preparations: different characteristics and their effect during inflammation induced by monosodium urate crystals in the rat subcutaneous air pouch. Rheumatology 2003, 42:1093–1100.

    Article  PubMed  CAS  Google Scholar 

  65. Kim KY, Schumacher HR, Hunsche E, et al.: A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003, 25:1593–1617. Excellent review of the epidemiology, treatment, and burden of illness for acute gout.

    Article  PubMed  Google Scholar 

  66. Anderson BE, Adams DR: Allopurinol hypersensitivity syndrome. J Drugs Dermatol 2002, 1:60–62.

    PubMed  Google Scholar 

  67. Hoffman LA: My gout and allopurinol desensitization. J Clin Rheumatol 2002, 8:354–357.

    Article  PubMed  Google Scholar 

  68. Perez-Ruiz F, Calabozo M, Pijoan JI, et al.: Effect of urate lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47:356–360.

    Article  PubMed  CAS  Google Scholar 

  69. Hanvivadhanakul P, Akkasilpa S, Deesomchok U: Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai 2002, 85(suppl):S40-S47.

    PubMed  Google Scholar 

  70. Tsutsumi Z, Moriwaki Y, Takahashi S, et al.: Oxidized lowdensity lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. Clin Chim Acta 2004, 339:117–122.

    Article  PubMed  CAS  Google Scholar 

  71. Arai M, Yokosuka O, Fujiwara K, et al.: Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastoenterol Hepatol 2002, 17:625–626.

    Article  Google Scholar 

  72. Franco A, Jimenez L, Torralba J, et al.: Acute uric acid nephropathy by overdosage of benziodarone in a renal transplant recipient. Nephron 2002, 92:746–747.

    Article  PubMed  Google Scholar 

  73. Kumar S, Gow P: A survey of indications, results and complication of surgery for tophaceous gout. N Z Med J 2002, 115:U109-U112.

    PubMed  Google Scholar 

  74. Lee SS, Lin SD, Lai CS, et al.: The soft-tissue shaving procedure for deformity management of chronic tophaceous gout. Ann Plast Surg 2003, 51:372–375.

    Article  PubMed  Google Scholar 

  75. Park Y-B, Park Y-S, Lee S-C, et al.: Clinical analysis of gouty patients with normouricaemia at diagnosis. Ann Rheum Dis 2003, 62:90–92.

    Article  PubMed  Google Scholar 

  76. Kramer HJ, Choi HK, Atkinson K, et al.: The association between gout and nephrolithiasis in men: the Health Professionals’ Follow-Up Study. Kidney Int 2003, 64:1022–1026.

    Article  PubMed  Google Scholar 

  77. Pak CY, Poindexter JR, Adams-Huet B, Pearle MS: Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 2003, 115:26–32.

    Article  PubMed  CAS  Google Scholar 

  78. Spieker LE, Ruschitzka FT, Lüscher TF, et al.: The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Fail 2002, 4:203–410.

    Google Scholar 

  79. Darmawan J, Rasker JJ, Nuralim H: The effect of control and self-medication of chronic gout in a developing country: outcome after 10 years. J Rheumatol 2003, 30:2437–2443.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical College of Pennsylvania Hospital, Drexel University College of Medicine, 3300 Henry Avenue, 19129, Philadelphia, PA, USA

    John S. Bomalaski MD

Authors
  1. John S. Bomalaski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mike A. Clark PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bomalaski, J.S., Clark, M.A. Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 6, 240–247 (2004). https://doi.org/10.1007/s11926-004-0075-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-004-0075-3

Keywords

Search

Navigation